Journals / Turkish Journal of Endocrinology and Metabolism / 2020 / Cilt: 24 - Sayı: 4

Demographic and Clinical Features of Medullary Thyroid Carcinoma

Medüller Tiroid Karsinomunun Demografik ve Klinik Özellikleri

Pages
253–260
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients with MTC should beevaluated to know if the disease is sporadic or hereditary.The small sample size in this study restricts the power ofstatistical analysis;therefore, further prospective studies arenecessary to reveal the other contributory prognostic factors in MTC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor affecting the parafollicular Ccells of the thyroid gland.
📊
Key Findings & Data:Material and Methods:A total of 36 patients with a confirmed MTC diagnosis basedon histopathological examination and underwent surgeryduring 2000–2015 were examined.
💡
Conclusion & Impact:Patients with MTC should beevaluated to know if the disease is sporadic or hereditary.The small sample size in this study restricts the power ofstatistical analysis;therefore, further prospective studies arenecessary to reveal the other contributory prognostic factors in MTC.
🔬Design:Review & Systematic Survey
📍Scope:2000–2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor affecting the parafollicular Ccells of the thyroid gland. This study aimedto analyze demographic and clinical factors that might affect the prognosis of MTC andevaluate the long-term outcomes of surgeryin MTC patients at a single center. Material and Methods:A total of 36 patients with a confirmed MTC diagnosis basedon histopathological examination and underwent surgeryduring 2000–2015 were examined. Archived files of thesepatients were reviewed, and data on clinical, biochemical,and radiological test results were assessed. Factors affecting disease-free survival were also evaluated. Results:Theduration of the follow-up of the patients was 80.3±76.1months. MEN2A was detected in three patients (8.3%).Twelve patients (33.3%) had metastasis at the time of diagnosis. During the follow-up period, local recurrence wasobserved in 13 (36.1%) patients. Nine patients (25%) presented metastasis at follow-up. The mean disease-free survival was high in sporadic MTC compared to hereditary MTC.Conclusion: The study observed asignificant contributiontothe hereditary nature of the disease on prognosis. However,other prognostic factors such as gender, nodule characteristics, recurrence and metastasis, and treatmentmodalities did differsignificant. Patients with MTC should beevaluated to know if the disease is sporadic or hereditary.The small sample size in this study restricts the power ofstatistical analysis;therefore, further prospective studies arenecessary to reveal the other contributory prognostic factors in MTC.

Özet

Amaç: Medüller tiroid karsinom (MTK), tiroid bezinin parafoliküler C hücrelerinin nadir görülen agresif seyirli bir nöroendokrin tümörüdür. Çalışmanın amacı, merkezimizde opere olan MTK’lı hastalarda prognozu etkileyen demografik ve klinik faktörleri analiz etmek ve hastalığın uzun dönem sonuçlarını değerlendirmektir. Gereç ve Yöntemler: Çalışmamıza, merkezimizde 2000-2015 yılları arasında opere olup postoperatif histopatolojik değerlendirmede MTK tanısı alan toplam 36 hasta dâhil edildi. Tüm hastaların arşiv dosyaları gözden geçirildi ve klinik, biyokimyasal ve radyolojik verileri incelendi. Hastalıksız sağ kalımı etkileyen faktörler analiz edildi. Bulgular: Çalışmamızda hastaların ortalama takip süresi 80.3±76.1 aydı. Üç hastada (%8,3) MEN2A mevcuttu. On iki hastada (%33,3) tanı anında metastaz vardı. Takip süresince hastaların 13’ünde (%36,1) lokal nüks gözlendi. Dokuz hastada (%25) izleminde metastaz geliştiği görüldü. Ortalama hastalıksız sağ kalım, kalıtsal MTK ile karşılaştırıldığında sporadik MTK'da yüksekti. Sonuç: Çalışmamızda, kalıtsal hastalığın varlığının prognoza önemli katkısı olduğu saptandı. Bununla birlikte, cinsiyet, nodül özellikleri, nüks, metastaz varlığı ve tedavi yöntemleri gibi diğer faktörlerin prognoz üzerinde anlamlı bir farka yol açmadığı gözlendi. MTK’lı hastalar, hastalığın sporadik veya kalıtsal olup olmadığı açısından değerlendirilmelidir. Çalışmamızdaki az sayıda hasta istatistiksel analizin gücünü kısıtladığından, MTK’ya katkıda bulunan prognostik faktörleri saptamak için prospektif çalışmalara ihtiyaç duyulmaktadır.

🔖

Cite This Article

ERSOY, C., ŞİŞMAN, P., GÜL, Ö. Ö., CANDER, S., BİÇER, B., ÖZTOP, H., ERTÜRK, E., OCAKOĞLU, G. (2022). Demographic and Clinical Features of Medullary Thyroid Carcinoma. Turkish Journal of Endocrinology and Metabolism, Cilt: 24 - Sayı: 4, 253–260. https://ajindex.com/articles/654476

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Geller G, Laskin J, Cheung WY, Ho C. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy. Thyroid Res. 2017
  2. [Crossref] [PubMed] [PMC] 2. Calvo J, Torrealba G, Sáenz A, Santamaría C, Morera E, Alvarado S, Roa Y, González M. Genetic and clinical features of medullary thyroid carcinoma: the experience of a single center in Costa Rica. J Cancer Epidemiol. 2016
  3. 9637173. [Crossref] [PubMed] [PMC] 3. Maciel LMZ, Magalhães PKR. Medullary thyroid carcinoma - adverse events during systemic treatment: risk-benefit ratio. Arch Endocrinol Metab. 2017
  4. [Crossref] [PubMed] 4. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG
  5. American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015
  6. [Crossref] [PubMed] [PMC] 5. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC, Rubello D. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007
  7. [Crossref] [PubMed] 6. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab. 2005
  8. [Crossref] [PubMed] 7. Lee CR, Lee S, Son H, Ban E, Kang SW, Lee J, Jeong JJ, Nam KH, Chung WY, Park CS. Medullary thyroid carcinoma: a 30-year experience at one institution in Korea. Ann Surg Treat Res. 2016
  9. [Crossref] [PubMed] [PMC] 8. Nelkin B. Recent advances in the biology and therapy of medullary thyroid carcinoma. F1000Res. 2017
  10. [Crossref] [PubMed] [PMC] 9. Kim BH, Kim IJ. Recent updates on the management of medullary thyroid carcinoma. Endocrinol Metab (Seoul). 2016
  11. [Crossref] [PubMed] [PMC] 10.Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J Med. 1997
  12. [Crossref] [PubMed] 11.Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010
  13. [Crossref] [PubMed] 12.Pellegriti G, Leboulleux S, B